fashion -WSS

fashion

author：leisure time 2025-09-30 08:52:33 - browse：374

The FDA building -- First Opinion coverage from STAT — Adobe

A panel of expert advisers to the Food and Drug Administration on Friday voted in favor of expanding the use of CAR-T therapy in blood cancer, despite concerns about the powerful treatment’s side effects.

The group voted 11-0 that the benefits of Carvykti, a CAR-T medicine from Johnson & Johnson and Legend Biotech, outweighed its risk for patients with multiple myeloma whose disease has persisted despite initial treatment. The same panel voted 8-3 in favor of Abecma, from Bristol Myers Squibb and 2seventy Bio, for multiple myeloma patients who’ve received at least two lines of therapy. Currently both medicines are approved only for patients who have been treated for myeloma with four or more medications.

In clinical trials, each drug proved to significantly delay disease progression compared to standard therapy. But zooming in on the data, the FDA observed an alarming imbalance of deaths in the early months of both studies, finding that more patients in the CAR-T group died of myeloma or side effects than those receiving the standard of care.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Gilead might be held responsible for not developing a drug

WSS

Disclosing genetic information: not as worrisome as once feared

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Biden report: The neurospychology of memory and aging

With FDA staff opposed to Sarepta therapy, top official intervened

Doctors' information doesn't help them choose wisely when sick

STAT's guide to the next generation of CAR

hotspot

fashion

leisure time

Sports medicine is finally prioritizing gender equality

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

In age of alternative facts, a scholarly course on calling out crap

Biogen Alzheimer’s drug launch off to slow start

In age of alternative facts, a scholarly course on calling out crap

PhRMA lawsuit over Medicare drug price negotiation tossed

Wildfire smoke exposes gaps in outdoor worker protections

Readout LOUD podcast: How biotech is using artificial intelligence

In Memoriam: Notable people who died in 2023

Key House Republican on health care plans exit from Congress

knowledge

Why are elite athletes different? Take a look at their microbes

Senators start work on Medicare physician payment reform

To avoid data mishandling cases, universities eye AI and other tools

Readout LOUD podcast: How biotech is using artificial intelligence

Private equity deals in Medicare Advantage declines

Death of patient in Alzheimer’s trial raises question of possible risks

focus

leisure time

knowledge

hotspot